HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial

[1]  P. Reno,et al.  Missing Links. , 2017, Scientific American.

[2]  2. Classification and Diagnosis of Diabetes , 2016, Diabetes Care.

[3]  Clemens Lewold,et al.  Elevated Basal Insulin Secretion in Type 2 Diabetes Caused by Reduced Plasma Membrane Cholesterol , 2016, Molecular endocrinology.

[4]  C. Stehouwer,et al.  Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study , 2016, Scientific Reports.

[5]  Changhao Wu,et al.  Prognostic Usefulness of Serum Cholesterol Efflux Capacity in Patients With Coronary Artery Disease. , 2016, The American journal of cardiology.

[6]  S. Bakker,et al.  HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients. , 2016, Journal of the American Society of Nephrology : JASN.

[7]  S. Kahn,et al.  Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans , 2015, Diabetes Care.

[8]  J. Saleh.  Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors? , 2015, World journal of cardiology.

[9]  D. Rader,et al.  Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.

[10]  B. Nordestgaard,et al.  HDL Cholesterol and Risk of Type 2 Diabetes: A Mendelian Randomization Study , 2015, Diabetes.

[11]  A. von Eckardstein,et al.  HDLs, diabetes, and metabolic syndrome. , 2015, Handbook of experimental pharmacology.

[12]  Ben Ommen,et al.  The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition index after 2 years of intervention: the CORDIOPREV-DIAB randomised clinical trial , 2015, Diabetologia.

[13]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[14]  N. Kohno,et al.  Relationship between serum cholesterol efflux capacity and glucose intolerance in Japanese-Americans. , 2014, Journal of atherosclerosis and thrombosis.

[15]  M. Banach,et al.  Subfractions and subpopulations of HDL: an update. , 2014, Current medicinal chemistry.

[16]  V. Gebski,et al.  HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes , 2014, Diabetes Care.

[17]  Samia Mora,et al.  A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. , 2013, Clinical chemistry.

[18]  G. Navis,et al.  Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population , 2013 .

[19]  Amitava Banerjee,et al.  Tracking global funding for the prevention and control of noncommunicable diseases. , 2012, Bulletin of the World Health Organization.

[20]  R. Dullaart,et al.  Pancreatic β-cell function relates positively to HDL functionality in well-controlled type 2 diabetes mellitus. , 2012, Atherosclerosis.

[21]  P. Barter,et al.  The emerging role of HDL in glucose metabolism , 2012, Nature Reviews Endocrinology.

[22]  P. Barter,et al.  Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. , 2011, Circulation.

[23]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[24]  A. Thanopoulou,et al.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. , 2010, The New England journal of medicine.

[25]  R. DeFronzo.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 , 2010, Diabetologia.

[26]  D. Rader,et al.  The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Hayden,et al.  Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic β-Cell Dysfunction , 2008, Diabetes Care.

[28]  P. Giral,et al.  Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[29]  D. Sviridov,et al.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties , 2007, Diabetologia.

[30]  W. Benzer,et al.  Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? , 2005, Diabetes care.

[31]  D. Sviridov,et al.  Physical Fitness and Reverse Cholesterol Transport , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[32]  K. Rye,et al.  The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. , 2000, Biochemistry.

[33]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[34]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[35]  K. Johnson.  An Update. , 1984, Journal of food protection.

[36]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.